Clinical Trials Logo

Healthy Subjects clinical trials

View clinical trials related to Healthy Subjects.

Filter by:

NCT ID: NCT03648346 Completed - Healthy Subjects Clinical Trials

A Dose-escalation Clinical Trial After Multiple Dosing of HL217 Eye Drop in Healthy Male Subjects

Start date: April 4, 2018
Phase: Phase 1
Study type: Interventional

The study is a single center, double-blind, randomized, parallel group, multiple ascending dose study in 16 healthy male volunteers. Subjects will receive multiple eye drop doses during 14 days of the treatment (HL217 or placebo according to the randomization). There will be 2 cohorts of 8 subjects (6 HL217 vs 2 placebo) receiving the following doses: - Cohort 1 : two drops of 3 mg/mL of the treatment in one eye twice a day (low dose), - Cohort 2 : two drops of 3 mg/mL of the treatment in one eye 4 times a day (high dose).

NCT ID: NCT03647228 Completed - Cystic Fibrosis Clinical Trials

A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis

Start date: December 13, 2018
Phase: Phase 1
Study type: Interventional

This Phase 1/2a study is a double-blinded (subject and Investigator), randomized, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple nebulized doses of IONIS-ENaCRx.

NCT ID: NCT03644108 Completed - Healthy Subjects Clinical Trials

Study to Evaluate the Pharmacokinetics of Mucinex 600 mg Extended-release Bi-layer Tablet in Healthy Volunteers

Start date: June 4, 2009
Phase: Phase 1
Study type: Interventional

Evaluate the Pharmacokinetics of Mucinex® 600 mg Extended-Release Bi-Layer Tablet in Normal Healthy Subjects

NCT ID: NCT03644095 Completed - Healthy Subjects Clinical Trials

Bioequivalence Study Comparing Mucinex Extended-release 600 mg Tablets to Immediate-release Guaifenesin 600 mg in Healthy Volunteers

Start date: January 16, 2009
Phase: Phase 1
Study type: Interventional

Determine bioequivalence, safety and tolerability of guaifenesin extended-release 600 mg (Mucinex® SE) compared to an immediate-release syrup reference product in normal healthy subjects.

NCT ID: NCT03643575 Completed - Healthy Subjects Clinical Trials

Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers.

Start date: June 30, 2009
Phase: Phase 1
Study type: Interventional

Characterize the relative pharmacokinetics (PK) of 3 marketed products containing guaifenesin

NCT ID: NCT03642873 Completed - Healthy Subjects Clinical Trials

Study to Evaluate Drug-drug Interactions of Guaifenesin and Hydrocodone Bitartrate

Start date: May 5, 2007
Phase: Phase 1
Study type: Interventional

Determine and compare the plasma concentrations and safety and tolerability of Guaifenesin and hydrocodone bitartrate when they are administered alone or in combination to normal healthy male and/or female subjects.

NCT ID: NCT03642262 Completed - Healthy Subjects Clinical Trials

Mucinex® ER 600 mg Bi-layer Tablet Versus Guaifenesin Immediate Release (IR) 200 mg q4h

Start date: June 2, 2013
Phase: Phase 1
Study type: Interventional

Demonstrate bioequivalence of guaifenesin in Mucinex® extended release (ER) 600 mg tablet in normal healthy volunteers compared to the immediate release guaifenesin 200 mg tablet reference product marketed

NCT ID: NCT03634514 Not yet recruiting - Healthy Subjects Clinical Trials

Non-inferiority Evaluation of Pain Intensity After Biomatrop (Somatropin) Application in Relation to Hormotrop (Somatropin), in Healthy Subjects

Start date: August 27, 2018
Phase: Phase 4
Study type: Interventional

Randomized, Double-blind, Controlled, Crossover, in which 68 subjects (34 males and 34 females) will receive, in each stage, an application of 4 UI, subcutaneous, single dose, of the investigational drug (Recombinant Human Somatropin - Biomatrop) and the comparator (Recombinant Human Somatropin - Hormotrop) according to randomization to evaluate the Non-inferiority of Pain Intensity After the Application of Hormotrop, using Visual Analogue Scale (0-10cm) and record the incidence of adverse events.

NCT ID: NCT03633487 Completed - Healthy Subjects Clinical Trials

Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet

Start date: October 11, 2011
Phase: Phase 1
Study type: Interventional

Characterize and assess PK of guaifenesin in Mucinex® 1200 mg ER Bi-Layer Tablet

NCT ID: NCT03633448 Completed - Healthy Subjects Clinical Trials

Study to Evaluate the Pharmacokinetics of Guaifenesin in Adults and Adolescents

Start date: June 18, 2011
Phase: Phase 1
Study type: Interventional

Evaluate the pharmacokinetics (PK), Safety and tolerability of guaifenesin (Mucinex®) in an immediate-release formulation when a single dose is administered in adolescents and in adults when compared to Children.